>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
抗PD-1单抗联合治疗在胰腺癌中的研究进展
作者:周含煜1  恽骁2  徐克群1  朱颖蔚1 
单位:1. 南京医科大学附属常州二院肿瘤科, 江苏 常州 213003;
2. 南京医科大学附属常州二院肝胆外科, 江苏 常州 213003
关键词:胰腺癌 细胞表面程序性死亡受体-1 联合治疗 综述 
分类号:R735.9
出版年·卷·期(页码):2020·39·第三期(389-393)
摘要:

胰腺癌恶性度高,2019年我国胰腺癌患者5年生存率为7%~8%,目前治疗方法有限。随着抗细胞表面程序性死亡受体-1(PD-1)单抗治疗在黑色素瘤中取得巨大成功,免疫治疗成为恶性肿瘤治疗的热点,然而其在胰腺癌中的治疗效果未达预期。有研究提示联合治疗也许能提高抗PD-1单抗的疗效,在胰腺癌中已经开展的联合治疗方案有抗PD-1单抗联合化疗、放疗、肿瘤疫苗、CTLA-4抑制剂、分子靶向药物、其他免疫治疗等。现就抗PD-1单抗联合治疗胰腺癌的研究进展作一综述。

参考文献:

[1] ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health,2018,6(5):e555-557.
[2] HINZMAN C P,ALJEHANE L,BROWN-CLAY J D,et al.Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC[J].Carcinogenesis,2018,39(12):1548-1559.
[3] SEATON M,HANNA A,BOUTROS C,et al.Adjuvant therapy for pancreatic body or tail adenocarcinoma:a study of the National Cancer Database[J].Ther Adv Med Oncol,2019,11(1):1-12.
[4] 李海洋,戴素华,张伟,等.胃癌患者外周血T淋巴细胞亚群、PD-1水平的变化与预后的关系分析[J].现代医学,2018,46(10):1119-1122.
[5] OTT P A,BANG Y J,PIHA-PAUL S A,et al.T-cell-inflamed gene-expression profile,programmed death ligand 1 expression,and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers:KEYNOTE-028[J].J Clin Oncol,2019,37(4):318-327.
[6] LOOI C K,CHUNG F F,LEONG C O,et al.Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment[J].J Exp Clin Cancer Res,2019,38(1):162.
[7] GARRIS C S,ARLAUCKAS S P,KOHLER R H,et al.Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12[J].Immunity,2018,49(6):1148-1161.
[8] HU Z I,HELLMANN M D,WOLCHOK J D,et al.Acquired resistance to immunotherapy in MMR-D pancreatic cancer[J].J Immunother Cancer,2018,6(1):127.
[9] DIAB M,AZMI A,MOHAMMAD R,et al.Pharmacotherapeutic strategies for treating pancreatic cancer:advances and challenges[J].Expert Opin Pharmacother,2019,20(5):535-546.
[10] GOTWALS P,CAMERON S,CIPOLLETTA D,et al.Prospects for combining targeted and conventional cancer therapy with immunotherapy[J].Nat Rev Cancer,2017,17(5):286-301.
[11] WEISS G J,WAYPA J,BLAYDORN L,et al.A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)[J].Br J Cancer,2017,117(1):33-40.
[12] ZHANG Y,BUSH X,YAN B,et al.Gemcitabine nanoparticles promote antitumor immunity against melanoma[J].Biomaterials,2019,189(1):48-59.
[13] ORECCHIONI S,TALARICO G,LABANCA V,et al.Vinorelbine,cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma[J].Br J Cancer,2018,118(10):1329-1336.
[14] NISHIJIMA T F,SHACHAR S S,NYROP K A,et al.Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer:a meta-analysis[J].Oncologist,2017,22(4):470-479.
[15] WINOGRAD R,BYRNE K T,EVANS R A,et al.Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma[J].Cancer Immunol Res,2015,3(4):399-411.
[16] SUN D,MA J,WANG J,et al.Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer:a real-world study in Chinese cohort[J].Ther Clin Risk Manag,2018,14(1):1691-1700.
[17] WU Q,ALLOUCH A,MARTINS I,et al.Modulating both tumor cell death and innate immunity is essential for improving radiation therapy effectiveness[J].Front Immunol,2017,8(1):613.
[18] MAHMOOD J,SHUKLA H D,SOMAN S,et al.Immunotherapy,radiotherapy,and hyperthermia:a combined therapeutic approach in pancreatic cancer treatment[J].Cancers(Basel),2018,10(12):469.
[19] ERIC L,YEO C J,LILLEMOE K D,et al.A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma[J].Ann Surg,2011,253(2):328-335.
[20] HALL M,LIU H,MALAFA M,et al.Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors[J].J Immunother Cancer,2016,4(1):61.
[21] SOARES K C,RUCKI A A,WU A A,et al.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J].J Immunother,2015,38(1):1-11.
[22] SAUNG M T,MUTH S,DING D,et al.Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer[J].J Immunother Cancer,2018,6(1):118.
[23] WEI S C,LEVINE J H,COGDILL A P,et al.Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J].Cell,2017,170(6):1120-1133.
[24] TANVETYANON T,GRAY J E,ANTONIA S J.PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? [J].Expert Opin Biol Ther,2017,17(3):305-312.
[25] LIU Y,LIU Z,ZENG X,et al.Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma[J].BMC Cancer,2019,19(1):1193.
[26] LIN K,CHENG J,YANG T,et al.EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB[J].Biochem Biophys Res Commun,2015,463(1-2):95-101.
[27] SAHORA K,SCHINDL M,KUEHRER I,et al.A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer[J].Anticancer Res,2014,34(5):2377-2384.
[28] PATEL K,SIRAJ S,SMITH C,et al.Pancreatic cancer:an emphasis on current perspectives in immunotherapy[J].Crit Rev Oncog,2019,24(2):105-118.
[29] MAHALINGAM D,WILKINSON G A,ENG K H,et al.Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma:a phase Ib study[J] .Clin Cancer Res,2020,26(1):71-81.
[30] OSBORNE N,SUNDSETH R,BURKS J,et al.Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment[J].Cancer Immunol Immunother,2019,68(10):1635-1648.
[31] BASSANI-STERNBERG M,DIGKLIA A,HUBER F,et al.A phase Ib study of the combination of personalized autologous dendritic cell vaccine,aspirin,and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma-a proof of antigen discovery feasibility in three patients[J].Front Immunol,2019,10(1):1832.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405876 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364